Interestingly, these cells are known for their proliferation, recurrence, and resistance; hence, it has been suggested that anti-CD47 monoclonal antibodies may play a significant part in prevention and treatment of metastatic and recurrent ovarian cancer [146,155,156]. This evidence concerns the gene CD47 and ovarian carcinoma.